Global Psoriasis Treatment Market Outlook, 2031
The Global Psoriasis Treatment Market is segmented into By Type (Plaque Psoriasis, Psoriatic Arthritis, Others); By Drug Class (Interleukins Inhibitors, TNF Inhibitors, Corticosteroids, Vitamin D Analogs, Other Drug Classes); By Treatment Type (Biologics Drugs, Systemic Drugs, Topical Drugs, Phototherapy, Others); By Mode of Administration (Injectable, Oral, Topical, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-Commerce).
- Bonafide Research
- 02-01-2026
- Pages : 209
- Figures : 36
- Tables : 98
- Region : Global
- Category : Lifescience & Healthcare
- Healthcare
The Global Psoriasis Treatment market was valued at more than USD 30.10 Billion in 2025, and expected to reach a market size of more than USD 50.59 Billion by 2031 with the CAGR of
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 30.1 Billion
- Market Size (2031) USD 50.59 Billion
- CAGR (2026-2031) 9.27%
- Largest Market North America
- Fastest Market Asia-Pacific
- Format
Featured Companies
- 1. Sun Pharmaceutical Industries Limited
- 2. Johnson & Johnson,
- 3. Merck & Co., Inc.
- 4. Dr. Reddy’s Laboratories Limited
- 5. Pfizer Inc.
- 6. Novartis International AG
- 7. Biocon Limited
- 8. AbbVie Inc.
- 9. Bristol-Myers Squibb Company
- More...
Market Analysis
The global psoriasis treatment landscape has undergone a profound transformation over the past decade, evolving from primarily topical creams and phototherapy to highly targeted molecular therapies that focus on specific inflammatory pathways. Historically, treatments like methotrexate and cyclosporine dominated the therapeutic approach, offering broad immunosuppression but limited long-term disease control. The introduction of biologics changed this dynamic, with therapies such as AbbVie’s Skyrizi (risankizumab) and Johnson & Johnson’s Tremfya (guselkumab) providing highly specific inhibition of interleukin-23, enabling sustained skin clearance and improved patient quality of life. Novartis’ Cosentyx (secukinumab) helped establish interleukin-17 inhibition as a standard for moderate-to-severe psoriasis, while Amgen’s Otezla (apremilast) offered oral systemic therapy for patients seeking alternatives to injectables. The approval of Bimzelx (bimekizumab), a dual IL-17A/IL-17F inhibitor, marked a clinical milestone by enhancing skin clearance rates beyond earlier biologics, reshaping prescribing patterns in North America, Europe, and Asia. At the same time, biosimilars such as Teva/Alvotech’s SELARSDI (ustekinumab-aekn) have begun to influence pricing and accessibility, particularly in cost-sensitive markets. Advances in AI-driven drug design, exemplified by Takeda’s oral compound zasocitinib, demonstrate how machine learning is now being applied to identify novel therapeutic candidates more efficiently. These developments reflect a broader shift toward precision dermatology, integrating highly targeted biologics, patient-centered care pathways, and diagnostic innovations to manage the complex clinical and psychosocial burden of psoriasis. According to the research report "Global Psoriasis Treatment Market Outlook, 2031," published by Bonafide Research, the Global Psoriasis Treatment market was valued at more than USD 30.10 Billion in 2025, and expected to reach a market size of more than USD 50.59 Billion by 2031 with the CAGR of 9% from 2026-2031. Psoriasis treatment today is characterized by a diverse array of therapies spanning biologics, oral small molecules, biosimilars, and advanced topical agents, creating multiple options for patients and clinicians worldwide. Leading pharmaceutical companies including AbbVie, Johnson & Johnson, Novartis, Eli Lilly, and Amgen continue to drive the adoption of biologics, with Skyrizi, Tremfya, Cosentyx, Taltz (ixekizumab), and Humira frequently prescribed for moderate-to-severe plaque psoriasis across North America and Europe. In 2025, Boehringer Ingelheim secured approval for SPEVIGO (spesolimab-sbzo) to treat generalized pustular psoriasis, expanding options for rare and severe subtypes. Emerging therapies in the pipeline, such as Affibody AB’s izokibep targeting IL-17A and Xeligekimab (Jinlixi) in China, highlight ongoing regional diversification and innovation. Biosimilars including Imuldosa and Yesintek are gaining approvals that enhance accessibility and affordability in markets with price-sensitive patient populations. Novel topical formulations such as Arcutis Biotherapeutics’ Zoryve foam demonstrate innovation for mild to moderate psoriasis, focusing on convenience and improved adherence. Strategic collaborations and licensing agreements have accelerated global launches, allowing companies to bring next-generation therapies to multiple regions efficiently. These developments underscore a shift in the psoriasis treatment ecosystem, balancing high efficacy and safety of biologics with wider access through oral therapies, biosimilars, and innovative delivery systems. As a result, clinicians can now tailor treatment regimens more precisely to individual patient needs while addressing previously unmet clinical challenges, illustrating the ongoing evolution of care in this chronic and often debilitating condition.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamic
Market Drivers • Biologic Therapy Expansion:Widespread regulatory approvals for interleukin inhibitors such as secukinumab, ixekizumab, and guselkumab have significantly improved long-term disease control and remission durability. Large-scale clinical trials including FIXTURE and AMAGINE confirmed superior efficacy compared to conventional systemic drugs, accelerating physician adoption. Expanded reimbursement coverage across Europe, Japan, and Australia further increased accessibility, while updated clinical guidelines from dermatology associations increasingly recommend biologics as early-line options for moderate to severe disease management. • Rising Disease Awareness:Recognition of psoriasis as a systemic inflammatory disorder by organizations such as the World Health Organization and Global Psoriasis Atlas has improved diagnosis rates and early intervention. Public health campaigns, digital screening tools, and teledermatology platforms increased patient engagement, especially in Asia-Pacific and Latin America. Growing understanding of psoriasis links to cardiovascular disease, diabetes, and psoriatic arthritis has driven multidisciplinary treatment adoption, strengthening demand for long-term therapeutic solutions. Market Challenges • High Treatment Costs:Biologic therapies such as risankizumab and brodalumab remain expensive due to complex manufacturing processes, cold-chain logistics, and long clinical development timelines. Limited insurance coverage in developing regions and high out-of-pocket expenses restrict patient access. Even in developed healthcare systems, reimbursement restrictions and step-therapy protocols delay initiation, contributing to under-treatment and widening global access disparities. • Safety Monitoring Burden:Long-term immunomodulatory therapy requires continuous safety surveillance due to elevated risks of infection, malignancy, and immunogenicity. Regulatory agencies mandate extensive post-marketing surveillance and risk evaluation strategies, increasing operational complexity for manufacturers. Physicians face challenges in balancing efficacy with safety, particularly among elderly patients and those with comorbidities, limiting broader adoption in certain patient populations. Market Trends • Targeted Oral Innovation:Development of selective tyrosine kinase 2 inhibitors such as deucravacitinib reflects a shift toward oral therapies offering biologic-like efficacy with improved convenience. Late-stage clinical data demonstrated sustained disease clearance with favorable safety profiles, encouraging rapid regulatory approvals. This trend supports patient preference for non-injectable options, driving wider acceptance and reshaping long-term treatment paradigms. • Digital Care Integration:Adoption of artificial intelligence–enabled imaging tools and teledermatology platforms is transforming disease monitoring and treatment personalization. Automated lesion assessment systems validated in European and Asian clinical studies improved diagnostic precision and adherence tracking. Integration of remote consultations expanded specialist reach into underserved regions, accelerating early diagnosis and continuous care, particularly across emerging healthcare markets.
Segmentation
| By Type | Plaque Psoriasis | |
| Psoriatic Arthritis | ||
| Others | ||
| By Drug Class | Interleukins inhibitors | |
| TNF inhibitors | ||
| Corticosteroids | ||
| Vitamin D analogs | ||
| Other drug classes | ||
| By Treatment Type | Biologics Drugs | |
| Systemic Drugs | ||
| Topical Drugs | ||
| Phototherapy | ||
| Others | ||
| By Mode of Administration | Injectable | |
| Oral | ||
| Topical | ||
| Others | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| e-Commerce | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| MEA | United Arab Emirates | |
| Saudi Arabia | ||
| South Africa | ||
Plaque psoriasis is leading by type because it is the most prevalent form of psoriasis, accounting for the majority of diagnosed cases worldwide. Plaque psoriasis, also referred to as psoriasis vulgaris, dominates the global psoriasis treatment landscape largely due to its high prevalence and recognizable clinical presentation. Epidemiological studies suggest that plaque psoriasis represents approximately 80 to 90 percent of all psoriasis cases, affecting populations across North America, Europe, and Asia with significant consistency. The condition is characterized by raised, red, and scaly patches primarily located on the elbows, knees, scalp, and lower back, which are often visible and carry a substantial psychosocial burden for patients. This visibility prompts earlier clinical consultation and diagnosis, which drives the use of systemic therapies, biologics, and advanced topicals. Clinical management guidelines from institutions such as the American Academy of Dermatology and the European Academy of Dermatology emphasize the prioritization of plaque psoriasis in therapeutic development because of its chronicity, severity spectrum, and impact on quality of life. Additionally, plaque psoriasis frequently coexists with comorbidities such as psoriatic arthritis, cardiovascular disorders, and metabolic syndrome, which further necessitate aggressive and targeted treatment strategies. The high clinical awareness and patient demand for effective outcomes have led pharmaceutical companies to focus research and development efforts on therapies specifically addressing plaque psoriasis, resulting in a robust pipeline of biologics, small molecules, and novel topicals tailored for this form. Real-world data from healthcare systems in the United States and Germany demonstrate that patients with plaque psoriasis represent the majority of those receiving advanced systemic treatments, reinforcing the importance of this type in the overall market. Interleukin inhibitors are leading by drug class because they specifically target the immune pathways most responsible for psoriasis pathogenesis, offering superior efficacy and sustained disease control. The prominence of interleukin inhibitors in global psoriasis treatment is driven by their ability to precisely modulate the inflammatory cascade that underlies chronic plaque psoriasis and related forms. Unlike traditional systemic therapies such as methotrexate or cyclosporine, which suppress the immune system broadly, interleukin inhibitors selectively block key cytokines, including interleukin-17, interleukin-23, and interleukin-12, which are central to keratinocyte proliferation and immune-mediated skin inflammation. Drugs such as AbbVie’s Skyrizi, Johnson & Johnson’s Tremfya, Novartis’ Cosentyx, and Eli Lilly’s Taltz have demonstrated consistently high rates of skin clearance, with many patients achieving 90 percent improvement or complete remission of lesions in clinical trials. This targeted mechanism reduces off-target immunosuppression, lowering the incidence of infections and other adverse effects common with older systemic therapies, which increases physician confidence and patient adherence. Regulatory approvals across the United States, Europe, and Asia have reinforced their prominence, as agencies have recognized both efficacy and long-term safety profiles. Additionally, interleukin inhibitors often offer flexible dosing intervals, ranging from every four weeks to every twelve weeks depending on the molecule, which improves convenience and compliance for chronic management. The research and development pipeline continues to expand with next-generation interleukin inhibitors, including dual inhibitors like bimekizumab and emerging IL-23p19 targeted antibodies, reflecting both clinical need and commercial potential. Real-world evidence from specialty dermatology clinics in Germany, the United States, and Japan shows a strong preference among physicians for interleukin inhibitors over conventional systemic therapies, particularly in moderate-to-severe cases. Biologic drugs are leading by treatment type because they provide targeted therapy that achieves high efficacy and long-term disease control with improved patient outcomes compared to traditional treatments. The dominance of biologic drugs in the psoriasis treatment sector reflects the transformative impact of molecularly targeted therapy on chronic inflammatory skin disease management. Biologics, including monoclonal antibodies and fusion proteins, specifically inhibit the cytokines responsible for keratinocyte hyperproliferation and immune activation, offering a precision approach that older systemic therapies cannot match. Medications such as AbbVie’s Skyrizi, Johnson & Johnson’s Tremfya, Novartis’ Cosentyx, and Eli Lilly’s Taltz have established benchmarks for clinical outcomes, with trials showing high rates of complete or near-complete lesion clearance sustained over years of treatment. Biologics also have demonstrated efficacy in managing comorbid conditions like psoriatic arthritis, which affects a significant portion of psoriasis patients, making them a preferred option for comprehensive disease control. Their predictable safety profiles, documented through long-term extension studies and post-marketing surveillance, reduce concerns associated with broad immunosuppression, which were common with methotrexate or cyclosporine. The versatility of biologics, including varying dosing schedules that can range from weekly to quarterly injections, improves patient adherence and convenience, reinforcing their position as the first-line therapy for moderate-to-severe cases in clinical guidelines published by the American Academy of Dermatology and European dermatology societies. In addition, the growing introduction of biosimilars such as Imuldosa and Yesintek has expanded access to biologic treatment, particularly in cost-sensitive markets, without compromising efficacy. Real-world treatment data from dermatology centers in the United States, Germany, and Japan highlight that patients receiving biologics experience significant improvements in quality of life and work productivity, creating a strong preference among both clinicians and patients. Injectable administration is leading by mode because it enables precise dosing of biologics and small molecules that require systemic delivery to effectively manage moderate-to-severe psoriasis. The widespread use of injectable therapies in psoriasis management is primarily linked to their necessity for delivering biologics and certain systemic small molecules with optimal pharmacokinetics and targeted action. Injectable administration, whether subcutaneous or intravenous, ensures that drugs such as Skyrizi, Tremfya, Cosentyx, Taltz, and SPEVIGO achieve therapeutic concentrations directly in the bloodstream, which is critical for modulating interleukin pathways effectively. Subcutaneous injections also allow for self-administration at home, reducing the burden on patients compared to hospital-based intravenous treatments while maintaining high efficacy. Clinical trials have demonstrated that injectable biologics can achieve rapid onset of action, with many patients observing significant plaque reduction within weeks, an advantage not matched by oral or topical treatments for moderate-to-severe disease. Injectable dosing schedules vary from weekly to quarterly depending on the molecule, providing flexibility for chronic management and supporting adherence, which is particularly important given the long-term nature of psoriasis therapy. The precise delivery reduces variability in drug absorption, minimizes systemic side effects compared to oral immunosuppressants, and allows for titration or adjustment by dermatologists to achieve optimal clinical outcomes. Regulatory approvals across the United States, Europe, and Asia have reinforced injectables as the preferred route for advanced therapies, and real-world data from specialty dermatology clinics show high patient satisfaction with convenience, tolerability, and predictable results. Retail pharmacies are leading by distribution channel because they provide broad accessibility and convenient procurement for patients managing chronic psoriasis treatment regimens. The dominance of retail pharmacies as a distribution channel for psoriasis treatments is rooted in their ability to deliver medications directly to patients with ease, supporting ongoing adherence to chronic therapy. Patients with psoriasis, particularly those prescribed biologics, oral small molecules, or specialized topicals, benefit from the immediate availability and counseling provided by retail pharmacists, who often guide dosing schedules, storage requirements, and administration techniques. In many countries, retail pharmacies act as the primary touchpoint for prescription fulfillment, ensuring continuity of care between dermatology clinics and home-based treatment. This is especially critical for injectable therapies such as Skyrizi, Tremfya, Cosentyx, and Taltz, where patient education on proper subcutaneous administration and cold-chain handling is essential to maintain drug efficacy. Retail pharmacies also facilitate insurance claims, co-pay management, and patient assistance programs, which improve treatment accessibility and reduce barriers related to affordability. In regions like North America and Europe, extensive retail pharmacy networks and integration with electronic health records allow physicians to monitor adherence, provide refills efficiently, and coordinate care for patients with comorbid conditions like psoriatic arthritis or metabolic syndrome. Additionally, retail pharmacies support patient engagement by offering educational materials, counseling services, and occasional vaccination or wellness programs that intersect with chronic disease management, strengthening the connection between patients and their therapeutic regimens. Real-world data indicate that retail pharmacies serve as the most reliable distribution point for both urban and suburban populations, where access to specialty clinics may be limited, and patients prioritize convenience and ongoing support.
to Download this information in a PDF
Market Regional Insights
North America is leading region because it has advanced healthcare infrastructure, high adoption of innovative biologics, and strong regulatory support for new psoriasis therapies. North America’s leadership in the psoriasis treatment landscape is a result of a convergence of healthcare, regulatory, and commercial factors that favor rapid adoption of advanced therapies. The United States and Canada possess highly developed healthcare systems with extensive access to dermatology specialists, facilitating early diagnosis and comprehensive management of moderate-to-severe psoriasis. Regulatory agencies such as the Food and Drug Administration maintain clear and efficient pathways for approval of novel biologics and interleukin inhibitors, allowing companies like AbbVie, Johnson & Johnson, Novartis, and Eli Lilly to launch therapies such as Skyrizi, Tremfya, Cosentyx, and Taltz quickly and widely. Physicians in North America are generally well-informed regarding emerging therapeutic options and guideline-driven care, supporting widespread use of interleukin-targeted biologics that demonstrate superior efficacy and long-term disease control. The region also benefits from high patient awareness and demand for innovative treatments, reinforced by patient advocacy organizations, educational campaigns, and reimbursement mechanisms that reduce financial barriers to accessing advanced therapies. Specialty pharmacy networks, insurance coverage programs, and patient assistance initiatives further facilitate adherence and continuity of care. Real-world evidence from dermatology clinics in the United States shows that patients have higher access to cutting-edge injectable biologics compared to other regions, and clinical outcomes reflect the effective integration of new therapies into standard practice. Additionally, research and development hubs located in North America accelerate clinical trials, pipeline innovation, and real-world studies that contribute to the rapid adoption of next-generation treatments.
to Download this information in a PDF
Key Development
• In July 2025, Boehringer Ingelheim and LEO Pharma entered an exclusive global agreement to commercialize and further develop SPEVIGO (spesolimab) for generalized pustular psoriasis (GPP). The collaboration enhanced LEO Pharma’s and Boehringer’s impact in rare skin disease treatment. • In September 2024, Organon acquired Dermavant Sciences, including its FDA-approved non-steroidal topical therapy VTAMA (tapinarof) cream, 1% for plaque psoriasis. This move extended Organon’s dermatology capabilities into the U.S. market and strengthened its presence in immuno-dermatology. • In October 2023, Arcutis Biotherapeutics, Inc., a biopharmaceutical company received the U.S. FDA approval for the Supplemental New Drug Application (sNDA) to expand indication of Zoryve cream for tropically treating plaque psoriasis, comprising intertriginous areas, to children ages 6 to 11 years. • In March 2023, Bristol Myers Squibb received approval from the European Commission for Sotyktu to treat adult patients suffering from moderate-to-severe plaque psoriasis. • In September 2022, Bristol Myers Squibb received the FDA approval for Sotyktu, an oral, allosteric tyrosine kinase 2-inhibitor for treating adults suffering from moderate-to-severe plaque psoriasis.
Companies Mentioned
- Sun Pharmaceutical Industries Limited
- Johnson & Johnson,
- Merck & Co., Inc.
- Dr. Reddy’s Laboratories Limited
- Pfizer Inc.
- Novartis International AG
- Biocon Limited
- AbbVie Inc.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Eli Lilly and Company
- Amgen Inc
- Inmode Ltd
- Samsung Biologics Co., Ltd.
- C.H. Boehringer Sohn AG & Co. KG
- Almirall, S.A.
- LEO Pharma A/S
- UCB S.A.
- Arcutis Biotheraupatics, Inc.
- Alvotech SA
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Global Psoriasis Treatment Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Region
- 6.3. Market Size and Forecast, By Geography
- 6.4. Market Size and Forecast, By Type
- 6.5. Market Size and Forecast, By Drug Class
- 6.6. Market Size and Forecast, By Treatment Type
- 6.7. Market Size and Forecast, By Mode of Administration
- 6.8. Market Size and Forecast, By Distribution Channel
- 7. North America Psoriasis Treatment Market Outlook
- 7.1. Market Size By Value
- 7.2. Market Share By Country
- 7.3. Market Size and Forecast, By Type
- 7.4. Market Size and Forecast, By Drug Class
- 7.5. Market Size and Forecast, By Treatment Type
- 7.6. Market Size and Forecast, By Mode of Administration
- 7.7. Market Size and Forecast, By Distribution Channel
- 7.8. United States Psoriasis Treatment Market Outlook
- 7.8.1. Market Size by Value
- 7.8.2. Market Size and Forecast By Type
- 7.8.3. Market Size and Forecast By Treatment Type
- 7.8.4. Market Size and Forecast By Distribution Channel
- 7.9. Canada Psoriasis Treatment Market Outlook
- 7.9.1. Market Size by Value
- 7.9.2. Market Size and Forecast By Type
- 7.9.3. Market Size and Forecast By Treatment Type
- 7.9.4. Market Size and Forecast By Distribution Channel
- 7.10. Mexico Psoriasis Treatment Market Outlook
- 7.10.1. Market Size by Value
- 7.10.2. Market Size and Forecast By Type
- 7.10.3. Market Size and Forecast By Treatment Type
- 7.10.4. Market Size and Forecast By Distribution Channel
- 8. Europe Psoriasis Treatment Market Outlook
- 8.1. Market Size By Value
- 8.2. Market Share By Country
- 8.3. Market Size and Forecast, By Type
- 8.4. Market Size and Forecast, By Drug Class
- 8.5. Market Size and Forecast, By Treatment Type
- 8.6. Market Size and Forecast, By Mode of Administration
- 8.7. Market Size and Forecast, By Distribution Channel
- 8.8. Germany Psoriasis Treatment Market Outlook
- 8.8.1. Market Size by Value
- 8.8.2. Market Size and Forecast By Type
- 8.8.3. Market Size and Forecast By Treatment Type
- 8.8.4. Market Size and Forecast By Distribution Channel
- 8.9. United Kingdom (UK) Psoriasis Treatment Market Outlook
- 8.9.1. Market Size by Value
- 8.9.2. Market Size and Forecast By Type
- 8.9.3. Market Size and Forecast By Treatment Type
- 8.9.4. Market Size and Forecast By Distribution Channel
- 8.10. France Psoriasis Treatment Market Outlook
- 8.10.1. Market Size by Value
- 8.10.2. Market Size and Forecast By Type
- 8.10.3. Market Size and Forecast By Treatment Type
- 8.10.4. Market Size and Forecast By Distribution Channel
- 8.11. Italy Psoriasis Treatment Market Outlook
- 8.11.1. Market Size by Value
- 8.11.2. Market Size and Forecast By Type
- 8.11.3. Market Size and Forecast By Treatment Type
- 8.11.4. Market Size and Forecast By Distribution Channel
- 8.12. Spain Psoriasis Treatment Market Outlook
- 8.12.1. Market Size by Value
- 8.12.2. Market Size and Forecast By Type
- 8.12.3. Market Size and Forecast By Treatment Type
- 8.12.4. Market Size and Forecast By Distribution Channel
- 8.13. Russia Psoriasis Treatment Market Outlook
- 8.13.1. Market Size by Value
- 8.13.2. Market Size and Forecast By Type
- 8.13.3. Market Size and Forecast By Treatment Type
- 8.13.4. Market Size and Forecast By Distribution Channel
- 9. Asia-Pacific Psoriasis Treatment Market Outlook
- 9.1. Market Size By Value
- 9.2. Market Share By Country
- 9.3. Market Size and Forecast, By Type
- 9.4. Market Size and Forecast, By Drug Class
- 9.5. Market Size and Forecast, By Treatment Type
- 9.6. Market Size and Forecast, By Mode of Administration
- 9.7. Market Size and Forecast, By Distribution Channel
- 9.8. China Psoriasis Treatment Market Outlook
- 9.8.1. Market Size by Value
- 9.8.2. Market Size and Forecast By Type
- 9.8.3. Market Size and Forecast By Treatment Type
- 9.8.4. Market Size and Forecast By Distribution Channel
- 9.9. Japan Psoriasis Treatment Market Outlook
- 9.9.1. Market Size by Value
- 9.9.2. Market Size and Forecast By Type
- 9.9.3. Market Size and Forecast By Treatment Type
- 9.9.4. Market Size and Forecast By Distribution Channel
- 9.10. India Psoriasis Treatment Market Outlook
- 9.10.1. Market Size by Value
- 9.10.2. Market Size and Forecast By Type
- 9.10.3. Market Size and Forecast By Treatment Type
- 9.10.4. Market Size and Forecast By Distribution Channel
- 9.11. Australia Psoriasis Treatment Market Outlook
- 9.11.1. Market Size by Value
- 9.11.2. Market Size and Forecast By Type
- 9.11.3. Market Size and Forecast By Treatment Type
- 9.11.4. Market Size and Forecast By Distribution Channel
- 9.12. South Korea Psoriasis Treatment Market Outlook
- 9.12.1. Market Size by Value
- 9.12.2. Market Size and Forecast By Type
- 9.12.3. Market Size and Forecast By Treatment Type
- 9.12.4. Market Size and Forecast By Distribution Channel
- 10. South America Psoriasis Treatment Market Outlook
- 10.1. Market Size By Value
- 10.2. Market Share By Country
- 10.3. Market Size and Forecast, By Type
- 10.4. Market Size and Forecast, By Drug Class
- 10.5. Market Size and Forecast, By Treatment Type
- 10.6. Market Size and Forecast, By Mode of Administration
- 10.7. Market Size and Forecast, By Distribution Channel
- 10.8. Brazil Psoriasis Treatment Market Outlook
- 10.8.1. Market Size by Value
- 10.8.2. Market Size and Forecast By Type
- 10.8.3. Market Size and Forecast By Treatment Type
- 10.8.4. Market Size and Forecast By Distribution Channel
- 10.9. Argentina Psoriasis Treatment Market Outlook
- 10.9.1. Market Size by Value
- 10.9.2. Market Size and Forecast By Type
- 10.9.3. Market Size and Forecast By Treatment Type
- 10.9.4. Market Size and Forecast By Distribution Channel
- 10.10. Colombia Psoriasis Treatment Market Outlook
- 10.10.1. Market Size by Value
- 10.10.2. Market Size and Forecast By Type
- 10.10.3. Market Size and Forecast By Treatment Type
- 10.10.4. Market Size and Forecast By Distribution Channel
- 11. Middle East & Africa Psoriasis Treatment Market Outlook
- 11.1. Market Size By Value
- 11.2. Market Share By Country
- 11.3. Market Size and Forecast, By Type
- 11.4. Market Size and Forecast, By Drug Class
- 11.5. Market Size and Forecast, By Treatment Type
- 11.6. Market Size and Forecast, By Mode of Administration
- 11.7. Market Size and Forecast, By Distribution Channel
- 11.8. United Arab Emirates (UAE) Psoriasis Treatment Market Outlook
- 11.8.1. Market Size by Value
- 11.8.2. Market Size and Forecast By Type
- 11.8.3. Market Size and Forecast By Treatment Type
- 11.8.4. Market Size and Forecast By Distribution Channel
- 11.9. Saudi Arabia Psoriasis Treatment Market Outlook
- 11.9.1. Market Size by Value
- 11.9.2. Market Size and Forecast By Type
- 11.9.3. Market Size and Forecast By Treatment Type
- 11.9.4. Market Size and Forecast By Distribution Channel
- 11.10. South Africa Psoriasis Treatment Market Outlook
- 11.10.1. Market Size by Value
- 11.10.2. Market Size and Forecast By Type
- 11.10.3. Market Size and Forecast By Treatment Type
- 11.10.4. Market Size and Forecast By Distribution Channel
- 12. Competitive Landscape
- 12.1. Competitive Dashboard
- 12.2. Business Strategies Adopted by Key Players
- 12.3. Key Players Market Share Insights and Analysis, 2025
- 12.4. Key Players Market Positioning Matrix
- 12.5. Porter's Five Forces
- 12.6. Company Profile
- 12.6.1. AbbVie Inc.
- 12.6.1.1. Company Snapshot
- 12.6.1.2. Company Overview
- 12.6.1.3. Financial Highlights
- 12.6.1.4. Geographic Insights
- 12.6.1.5. Business Segment & Performance
- 12.6.1.6. Product Portfolio
- 12.6.1.7. Key Executives
- 12.6.1.8. Strategic Moves & Developments
- 12.6.2. Novartis AG
- 12.6.3. Johnson & Johnson
- 12.6.4. Pfizer Inc.
- 12.6.5. LEO Pharma A/S
- 12.6.6. Eli Lilly and Company
- 12.6.7. Amgen Inc.
- 12.6.8. Merck & Co., Inc.
- 12.6.9. Samsung Biologics Co., Ltd.
- 12.6.10. UCB S.A.
- 12.6.11. Sun Pharmaceutical Industries Ltd.
- 12.6.12. Arcutis Biotheraupatics, Inc.
- 12.6.13. Biocon Limited
- 12.6.14. C.H. Boehringer Sohn AG & Co. KG
- 12.6.15. Bristol-Myers Squibb Company
- 12.6.16. AstraZeneca plc
- 12.6.17. Galderma S.A.
- 12.6.18. Alvotech SA
- 12.6.19. Almirall, S.A.
- 12.6.20. Dr. Reddy’s Laboratories Ltd.
- 13. Strategic Recommendations
- 14. Annexure
- 14.1. FAQ`s
- 14.2. Notes
- 14.3. Related Reports
- 15. Disclaimer
Table 2: Influencing Factors for Psoriasis Treatment Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Psoriasis Treatment Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Psoriasis Treatment Market Size and Forecast, By Type (2020 to 2031F) (In USD Billion)
Table 8: Global Psoriasis Treatment Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)
Table 9: Global Psoriasis Treatment Market Size and Forecast, By Treatment Type (2020 to 2031F) (In USD Billion)
Table 10: Global Psoriasis Treatment Market Size and Forecast, By Mode of Administration (2020 to 2031F) (In USD Billion)
Table 11: Global Psoriasis Treatment Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 12: North America Psoriasis Treatment Market Size and Forecast, By Type (2020 to 2031F) (In USD Billion)
Table 13: North America Psoriasis Treatment Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)
Table 14: North America Psoriasis Treatment Market Size and Forecast, By Treatment Type (2020 to 2031F) (In USD Billion)
Table 15: North America Psoriasis Treatment Market Size and Forecast, By Mode of Administration (2020 to 2031F) (In USD Billion)
Table 16: North America Psoriasis Treatment Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 17: United States Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 18: United States Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 19: United States Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 20: Canada Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 21: Canada Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 22: Canada Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 23: Mexico Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 24: Mexico Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 25: Mexico Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 26: Europe Psoriasis Treatment Market Size and Forecast, By Type (2020 to 2031F) (In USD Billion)
Table 27: Europe Psoriasis Treatment Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)
Table 28: Europe Psoriasis Treatment Market Size and Forecast, By Treatment Type (2020 to 2031F) (In USD Billion)
Table 29: Europe Psoriasis Treatment Market Size and Forecast, By Mode of Administration (2020 to 2031F) (In USD Billion)
Table 30: Europe Psoriasis Treatment Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 31: Germany Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 32: Germany Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 33: Germany Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 34: United Kingdom (UK) Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 35: United Kingdom (UK) Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 36: United Kingdom (UK) Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 37: France Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 38: France Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 39: France Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 40: Italy Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 41: Italy Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 42: Italy Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 43: Spain Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 44: Spain Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 45: Spain Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 46: Russia Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 47: Russia Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 48: Russia Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 49: Asia-Pacific Psoriasis Treatment Market Size and Forecast, By Type (2020 to 2031F) (In USD Billion)
Table 50: Asia-Pacific Psoriasis Treatment Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)
Table 51: Asia-Pacific Psoriasis Treatment Market Size and Forecast, By Treatment Type (2020 to 2031F) (In USD Billion)
Table 52: Asia-Pacific Psoriasis Treatment Market Size and Forecast, By Mode of Administration (2020 to 2031F) (In USD Billion)
Table 53: Asia-Pacific Psoriasis Treatment Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 54: China Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 55: China Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 56: China Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 57: Japan Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 58: Japan Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 59: Japan Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 60: India Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 61: India Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 62: India Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 63: Australia Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 64: Australia Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 65: Australia Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 66: South Korea Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 67: South Korea Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 68: South Korea Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 69: South America Psoriasis Treatment Market Size and Forecast, By Type (2020 to 2031F) (In USD Billion)
Table 70: South America Psoriasis Treatment Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)
Table 71: South America Psoriasis Treatment Market Size and Forecast, By Treatment Type (2020 to 2031F) (In USD Billion)
Table 72: South America Psoriasis Treatment Market Size and Forecast, By Mode of Administration (2020 to 2031F) (In USD Billion)
Table 73: South America Psoriasis Treatment Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 74: Brazil Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 75: Brazil Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 76: Brazil Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 77: Argentina Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 78: Argentina Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 79: Argentina Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 80: Colombia Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 81: Colombia Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 82: Colombia Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 83: Middle East & Africa Psoriasis Treatment Market Size and Forecast, By Type (2020 to 2031F) (In USD Billion)
Table 84: Middle East & Africa Psoriasis Treatment Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)
Table 85: Middle East & Africa Psoriasis Treatment Market Size and Forecast, By Treatment Type (2020 to 2031F) (In USD Billion)
Table 86: Middle East & Africa Psoriasis Treatment Market Size and Forecast, By Mode of Administration (2020 to 2031F) (In USD Billion)
Table 87: Middle East & Africa Psoriasis Treatment Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 88: United Arab Emirates (UAE) Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 89: United Arab Emirates (UAE) Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 90: United Arab Emirates (UAE) Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 91: Saudi Arabia Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 92: Saudi Arabia Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 93: Saudi Arabia Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 94: South Africa Psoriasis Treatment Market Size and Forecast By Type (2020 to 2031F) (In USD Billion)
Table 95: South Africa Psoriasis Treatment Market Size and Forecast By Treatment Type (2020 to 2031F) (In USD Billion)
Table 96: South Africa Psoriasis Treatment Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 97: Competitive Dashboard of top 5 players, 2025
Table 98: Key Players Market Share Insights and Analysis for Psoriasis Treatment Market 2025
Figure 1: Global Psoriasis Treatment Market Size (USD Billion) By Region, 2024 & 2030
Figure 2: Market attractiveness Index, By Region 2030
Figure 3: Market attractiveness Index, By Segment 2030
Figure 4: Global Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Psoriasis Treatment Market Share By Region (2025)
Figure 6: North America Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Psoriasis Treatment Market Share By Country (2025)
Figure 8: US Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Psoriasis Treatment Market Share By Country (2025)
Figure 13: Germany Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Psoriasis Treatment Market Share By Country (2025)
Figure 21: China Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Psoriasis Treatment Market Share By Country (2025)
Figure 28: Brazil Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Psoriasis Treatment Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Psoriasis Treatment Market
Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (23 May, 2026)
- Notify To Team (23 May, 2026)
- Report updation (24 May, 2026)
- Report Quality Check (24 May, 2026)
- Report Dispatch (25 May, 2026)
- Hard Copy
Recently Viewed Products
Global Psoriasis Treatment Market Outlook, 2031
We are friendly and approachable, give us a call.